Written question asked by David Kidney (Labour) on Friday, 18 February 2005, in the House of Commons. It was due for an answer on Tuesday, 22 February 2005. It was answered by Baroness Winterton of Doncaster (Labour) on Tuesday, 22 February 2005 on behalf of the Department of Health.

Dept of Health

Question: To ask the Secretary of State for Health, pursuant to his Answer of 3 February 2005, 430 c1117W, on Enbrel, if he will refer the drug Enbrel to the National Institute for Clinical Excellence in relation to its prescription in cases of juvenile arthritis.

Answer: Mr. Kidney: To ask the Secretary of State for Health pursuant to his answer of 3 February 2005, Official Report, column 1117W, on Enbrel, if he will refer the drug Enbrel to the National Institute for Clinical Excellence in relation to its prescription in cases of juvenile arthritis. [217166] Ms Rosie Winterton: The National Institute for Clinical Excellence (NICE) issued appraisal 2002/016 on 22 March 2002, which addressed the use of Etanercept (Enbrel) for the treatment of juvenile idiopathic arthritis and Etanercept and Infliximab for rheumatoid arthritis. Further information is available on the NICE website at www.nice.org.uk.

Secondary information